Pharmakotherapie der therapieresistenten Schizophrenie

Viele schizophrene Patienten sprechen auf die Behandlung mit dem ersten Antipsychotikum nicht an, selbst bei adäquater Therapie. Oft sind mehrere Therapieversuche nötig, um die Symptomatik genügend zu verbessern. Je nach Ausgangslage und Zielsymptomatik (Positiv- oder Negativsymptomatik, depressive Symptome) erreicht man ein optimales Behandlungsergebnis über verschiedene Behandlungsstrategien, z. B. Dosiserhöhung, Kombination oder Augmentation.

Kernaussagen

• Behandlungsresistenz sollte nach standardisierten Kriterien definiert werden.

• Verschiedene Faktoren, insbesondere die Compliance, beeinflussen das Auftreten von Therapieresistenz entscheidend.

• Eine Monotherapie sollte immer präferiert werden.

• Clozapin ist Behandlung der ersten Wahl bei Therapieresistenz und die Therapie sollte engmaschig überwacht werden.

• Falls Clozapin nicht verwendet werden kann, sollte ein anderes Antipsychotikum der 2. Generation verwendet werden – vorzugsweise Risperidon oder Olanzapin.

• Ein Wechsel des Antipsychotikums sollte immer auf ein Präparat mit einem anderen Rezeptorbindungsprofil erfolgen.

• Eine Kombination von Clozapin mit einem anderen Präparat der 2. Generation (z. B. Aripiprazol) kann im Einzelfall sinnvoll sein.

• Die Augmentation sollte nach der Zielsymptomatik erfolgen (z. B. Negativsymptome).

• Besonders bei der Kombination von 2 Antipsychotika sollten Nebenwirkungen engmaschig kontrolliert werden.

• In besonders schweren Fällen kann eine EKT zur Verbesserung der Symptomatik führen.

• Generell gibt es wenig Evidenz für behandlungsresistente Patienten.

Schlüsselwörter

Schizophrenie - Therapieresistenz - Pharmakotherapie - Clozapin

Publication History

Publication Date:
07 May 2019 (online)

• Literatur

• 1 GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1603-1658 doi:10.1016/S0140-6736(16)31460-X
• 2 Marwaha S, Johnson S. Schizophrenia and employment – a review. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 337-349
• 3 Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005; 62: 247-253 doi:10.1001/archpsyc.62.3.247
• 4 Hjorthøj C, Stürup AE, McGrath JJ. et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 2017;
• 5 Lehman AF, Lieberman JA, Dixon LB. et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161: 1-56
• 6 Leucht S, Kane JM, Etschel E. et al. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006; 31: 2318-2325
• 7 Andreasen N, Carpenter W, Kane J. et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 62: 441-449
• 8 Howes OD, McCutcheon R, Agid O. et al. Treatment-resistant schizophrenia: Treatment response and resistance in psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry 2017; 174: 216-229 doi:10.1176/appi.ajp.2016.16050503
• 9 Kane JM, Honigfeld G, Singer J. et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796
• 10 Meltzer HY. Commentary: defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16: 563-565
• 11 Meltzer HY. Treatment-resistant schizophrenia–the role of clozapine. Curr Med Res Opin 1997; 14: 1-20 doi:10.1185/03007999709113338
• 12 Aleman A, Lincoln TM, Bruggeman R. et al. Treatment of negative symptoms: Where do we stand, and where do we go?. Schizophr Res 2017; 186: 55-62 doi:10.1016/j.schres.2016.05.015
• 13 Samara MT, Nikolakopoulou A, Salanti G. et al. How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials. Schizophr Bull 2018;
• 14 Zhu Y, Li C, Huhn M. et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. Eur Neuropsychopharmacol 2017; 27: 835-844 doi:10.1016/j.euroneuro.2017.06.011
• 15 Samara MT, Leucht C, Leeflang MM. et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: A diagnostic test review. Am J Psychiatry 2015; 172: 617-629 doi:10.1176/appi.ajp.2015.14101329
• 16 Hasan A, Falkai P, Wobrock T. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13: 318-378 doi:10.3109/15622975.2012.696143
• 17 Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79-91
• 18 Davis JM, Chen N. Dose-response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24: 192-208
• 19 Hiemke C, Bergemann N, Clement HW. et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: 9-62 doi:10.1055/s-0043-116492
• 20 Samara MT, Klupp E, Helfer B. et al. Increasing antipsychotic dose for non response in schizophrenia. Cochrane Database Syst Rev 2018; (05) CD011883
• 21 Leucht S, Cipriani A, Spineli L. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 2013; 382: 951-962 doi:10.1016/S0140-6736(13)60733-3
• 22 Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics?: A review of the evidence. Neuropsychopharmacology 1998; 18: 63-101
• 23 Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010; 167: 763-772 doi:10.1176/appi.ajp.2009.09040598
• 24 Lieberman JA, Stroup TS, McEvoy JP. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223 doi:10.1056/NEJMoa051688
• 25 Buckley PF. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 2007; 68 Suppl 6: 5-9
• 26 Essock SM, Hargreaves WA, Covell NH. et al. Clozapineʼs effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996; 32: 683-697
• 27 Jones PB, Barnes TR, Davies L. et al. Randomized controlled trial of the effect on Quality of Life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS1). Arch Gen Psychiatry 2006; 63: 1079-1087 doi:10.1001/archpsyc.63.10.1079
• 28 Chakos M, Lieberman J, Hoffman E. et al. Effectiveness of second generation antipsychotics for treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-526
• 29 Samara MT, Dold M, Gianatsi M. et al. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. JAMA Psychiatry 2016; 73: 199-210 doi:10.1001/jamapsychiatry.2015.2955
• 30 Siskind D, McCartney L, Goldschlager R. et al. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016; 209: 385-392 doi:10.1192/bjp.bp.115.177261
• 31 Tiihonen J, Haukka J, Taylor M. et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011; 168: 603-609
• 32 Kahn RS, van Winter Rossum I, Leucht S. et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 2018; 5: 797-807 doi:10.1016/S2215-0366(18)30252-9
• 33 Gallego JA, Nielsen J. et al. Hert M de et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012; 11: 527-542 doi:10.1517/14740338.2012.683523
• 34 Correll CU, Rummel-Kluge C, Corves C. et al. Antipsychotic combinations vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35: 443-457 doi:10.1093/schbul/sbn018
• 35 Galling B, Roldán A, Hagi K. et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 2017; 16: 77-89 doi:10.1002/wps.20387
• 36 Veerman SR, Schulte PF, Begemann MJ. et al. Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Pharmacopsychiatry 2014; 47: 231-238 doi:10.1055/s-0034-1385930
• 37 Barnes TR, Leeson VC, Paton C. et al. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health Technol Assess 2017; 21: 1-56 doi:10.3310/hta21490
• 38 Fleischhacker WW, Heikkinen ME, Olié JP. et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 13: 1115-1125 doi:10.1017/S1461145710000490
• 39 Dold M, Li C, Gillies D. et al. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol 2013; 23: 1023-1033 doi:10.1016/j.euroneuro.2013.03.001
• 40 Sommer IE, Begemann MJ, Temmerman A. et al. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 2012; 38: 1003-1011 doi:10.1093/schbul/sbr004
• 41 Helfer B, Samara MT, Huhn M. et al. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. Am J Psychiatry 2016; 173: 876-886 doi:10.1176/appi.ajp.2016.15081035
• 42 Petrides G, Malur C, Braga RJ. et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry 2015; 172: 52-58 doi:10.1176/appi.ajp.2014.13060787
• 43 Morrison AP, Pyle M, Gumley A. et al. Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. Lancet Psychiatry 2018;
• 44 Gardner DM, Murphy AL, OʼDonnell H. et al. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686-693 doi:10.1176/appi.ajp.2009.09060802